Estonian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
dyslipidemias/turse
Link salvestatakse lõikelauale
Leht 1 alates 123 tulemused
Dyslipidemia and Diabetic Macular Edema: A Systematic Review and Meta-Analysis.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
OBJECTIVE
A systematic review and meta-analysis of dyslipidemia and diabetic macular edema (DME).
CONCLUSIONS
Diabetic macular edema causes impairment of vision in patients with diabetes, and dyslipidemia has been reported as a risk factor for its development. A systematic review with a
Hyperreflective foci in diabetic macular edema with serous retinal detachment: association with dyslipidemia.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Incidence and Characteristics of Patients with Visual Impairment due to Macular Edema Secondary to Retinal Vein Occlusion in a Representative Canadian Cohort.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Retinal vein occlusion (RVO) is an obstruction of the retinal venous system, and macular edema (ME) is a complication of RVO that can lead to blindness. The Canadian incidence of visual impairment (VI) due to ME secondary to RVO is unknown. This observational, retrospective study used records from
Retinal oximetry during treatment of retinal vein occlusion by ranibizumab in patients with high blood pressure and dyslipidemia.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND
In the present study, we examined retinal vascular oxygen saturation in patients with retinal vein occlusion (RVO), high blood pressure (HBP) and dyslipidemia, before and during intravitreal vascular endothelial growth factor (VEGF) injection (ranibizumab).
METHODS
We retrospectively
The Role of Dyslipidemia Control in the Progression of Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Diabetic retinopathy (DR) is a common microvascular complication of diabetes mellitus (DM) and is considered as the leading cause of visual impairment in working-aged adults worldwide. Dyslipidemia has been associated with DR, but not with progression to the proliferative form of DR, although the
Atorvastatin for diabetic macular edema in patients with diabetes mellitus and elevated serum cholesterol.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
OBJECTIVE
To determine the efficacy of atorvastatin in reducing hard exudates and diabetic macular edema.
METHODS
An uncontrolled clinical case series included 18 eyes with diabetic maculopathy and an elevated baseline lipid profile. All patients were treated with atorvastatin. Ophthalmologic
Serum and aqueous humor vitamin D levels in patients with diabetic macular edema.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Revisiting secondary amyloidosis for an inadequately investigated feature: dyslipidemia.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Secondary amyloidosis is the most frequent form of the systemic amyloidosis around the world. Data on frequency and nature of dyslipidemia in patients with secondary amyloidosis are not conclusive. We evaluated the lipid abnormalities and their association with clinical and laboratory
Diffuse macular edema in niacin-induced maculopathy may resolve with dosage decrease.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
OBJECTIVE
To report on a patient with niacin-induced cystic maculopathy that resolved with dosage decrease, not discontinuation, of niacin therapy for dyslipidemia.
METHODS
Retrospective case report. The patient was being followed for vision changes, but his niacin therapy was managed
Identifying risk factors for clinically significant diabetic macula edema in patients with type 2 diabetes mellitus.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
It is known that clinic blood pressure (BP), gender, cigarette smoking, dyslipidemia, anemia and thiazolidenediones (TZD) treatment are predictors for clinically significant diabetic macula edema (CSDME). We examined a most risky factor for CSDME in Japanese patients with type 2 diabetes mellitus
Serological inflammatory factors as biomarkers for anatomic response in diabetic macular edema treated with anti-VEGF.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
OBJECTIVE
To study the relationship between systemic pro-inflammatory factors and macular structural response to intravitreal bevacizumab for diabetic macular edema (DME).
METHODS
Prospective study including 30 cases with DME, treated with bevacizumab and a minimum follow-up of 6 months. All cases
The efficacy and safety of ezetimibe for treatment of dyslipidemia after heart transplantation.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND
Statins, although the treatment of choice for dyslipidemia after heart transplantation (HT), are not always well tolerated or effective. In such cases, administration of ezetimibe may be useful.
OBJECTIVE
The aim of this study was to assess the efficacy and safety of ezetimibe, with or
Observational study to evaluate the safety and efficacy of saroglitazar in Indian diabetic dyslipidemia patients.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Saroglitazar is a dual PPAR α/γ agonist approved in India for the management of diabetic dyslipidemia.
OBJECTIVE
The objective of this study was to evaluate the safety and efficacy of saroglitazar 4 mg once daily in clinical practice.
METHODS
This was an observational, multicenter, single-arm study.
Diabetic macular edema: new concepts in patho-physiology and treatment.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Diabetic macular edema (DME), a serious eye complication caused primarily by hyperglycemia, is one of the major causes of blindness. DME, which is characterized by cystic retinal thickening or lipid deposition, is prone to relapse after successful treatment. DME is a complex pathological process
Cotton Wool Spots after Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Associated with Central Retinal Vein Occlusion.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
OBJECTIVE
To report a case series, whereby we encountered a transient increase in retinal cotton wool spots (CWS) following anti-vascular endothelial growth factor (anti-VEGF) therapy for the treatment of macular edema secondary to central retinal vein occlusion (CRVO).
METHODS
Eighteen eyes were
Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus
- Töötab 55 keeles
- Taimsed ravimid, mida toetab teadus
- Maitsetaimede äratundmine pildi järgi
- Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
- Lugege oma otsinguga seotud teaduspublikatsioone
- Otsige ravimtaimi nende mõju järgi
- Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega
Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel
